A potential predictive marker for response to interferon in malignant melanoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The methylthioadenosine phosphorylase (mtap) gene is frequently deleted in various cancers, particularly on chromosome 9p21.
• Loss of MTAP expression, often due to promoter hypermethylation, is observed in malignant melanoma.
• MTAP loss is linked to increased tumor invasion, metastasis, and resistance to therapies.

Purpose of the Study:

• To investigate the role of MTAP expression in malignant melanoma.
• To explore the association between MTAP loss and therapeutic response, specifically to interferon therapy.
• To evaluate the potential of MTAP status as a predictive biomarker for interferon treatment.

Main Methods:

• Analysis of MTAP expression in malignant melanoma samples (in vitro and in vivo).
• Investigation of the regulatory mechanisms of MTAP loss, including promoter hypermethylation.
• Examination of the impact of MTAP loss on tumor invasion and metastasis.
• Assessment of the effect of MTAP loss on interferon-regulated signaling pathways, such as STAT signaling.

Main Results:

• Loss of MTAP expression was confirmed in malignant melanoma, primarily regulated by promoter hypermethylation.
• MTAP loss was associated with enhanced tumor invasion and metastasis.
• MTAP deficiency was implicated in the lack of therapeutic response in recurrent melanoma patients.
• Loss of MTAP was shown to inhibit interferon-regulated STAT signaling pathways, leading to treatment ineffectiveness.

Conclusions:

• MTAP functions as a tumor suppressor and its loss impacts melanoma progression.
• MTAP loss confers resistance to interferon therapy by disrupting STAT signaling.
• Determining MTAP status in primary tumors could aid in patient selection for interferon treatment, optimizing therapeutic outcomes.